Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes"

Affiliations

¹ Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.
² Gastroenterology Unit, Department of Oncological Gastrointestinal Surgery, S. Maria del Prato Hospital, Feltre, Italy.

Comment

Sonia Facchin et al. Neurogastroenterol Motil. 2021 Jan.

. 2021 Jan;33(1):e14054.

doi: 10.1111/nmo.14054. Epub 2020 Dec 4.

¹ Department of Surgery, Oncology and Gastroenterology (DISCOG), University Hospital of Padua, Padua, Italy.
² Gastroenterology Unit, Department of Oncological Gastrointestinal Surgery, S. Maria del Prato Hospital, Feltre, Italy.

No abstract available

Keywords: 16S metabarcoding; Gut Inflammation; SCFA; inflammatory bowel disease; prebiotics.

Comment on

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.
Facchin S, Vitulo N, Calgaro M, Buda A, Romualdi C, Pohl D, Perini B, Lorenzon G, Marinelli C, D'Incà R, Sturniolo GC, Savarino EV. Facchin S, et al. Neurogastroenterol Motil. 2020 Oct;32(10):e13914. doi: 10.1111/nmo.13914. Epub 2020 May 31. Neurogastroenterol Motil. 2020. PMID: 32476236 Free PMC article. Clinical Trial.
Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes.
Sitkin S, Vakhitov T, Pokrotnieks J. Sitkin S, et al. Neurogastroenterol Motil. 2021 Jan;33(1):e14038. doi: 10.1111/nmo.14038. Epub 2020 Nov 22. Neurogastroenterol Motil. 2021. PMID: 33222317 No abstract available.